Published in Cholesterol on October 17, 2012
Alzheimer's disease (AD) as a disorder of the plasma membrane. Front Physiol (2013) 0.92
Cholesterol homeostasis: a key to prevent or slow down neurodegeneration. Front Physiol (2013) 0.84
Delivery of circulating lipoproteins to specific neurons in the Drosophila brain regulates systemic insulin signaling. Elife (2014) 0.83
Molecular mechanisms underlying the effects of statins in the central nervous system. Int J Mol Sci (2014) 0.83
Cervical lymph node diseases in children. GMS Curr Top Otorhinolaryngol Head Neck Surg (2014) 0.81
Amyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta pores. Yale J Biol Med (2016) 0.81
Canonical microRNAs Enable Differentiation, Protect Against DNA Damage, and Promote Cholesterol Biosynthesis in Neural Stem Cells. Stem Cells Dev (2016) 0.80
Alteration of serum lipid profile, SRB1 loss, and impaired Nrf2 activation in CDKL5 disorder. Free Radic Biol Med (2015) 0.79
The multifaceted role of astrocytes in regulating myelination. Exp Neurol (2016) 0.79
Neurometabolic roles of ApoE and Ldl-R in mouse brain. J Bioenerg Biomembr (2015) 0.79
Suppression of brain cholesterol synthesis in male Mecp2-deficient mice is age dependent and not accompanied by a concurrent change in the rate of fatty acid synthesis. Brain Res (2016) 0.77
Role of LDL cholesterol and endolysosomes in amyloidogenesis and Alzheimer's disease. J Neurol Neurophysiol (2014) 0.77
TransOmic analysis of forebrain sections in Sp2 conditional knockout embryonic mice using IR-MALDESI imaging of lipids and LC-MS/MS label-free proteomics. Anal Bioanal Chem (2016) 0.77
Global Mapping of Traditional Chinese Medicine into Bioactivity Space and Pathways Annotation Improves Mechanistic Understanding and Discovers Relationships between Therapeutic Action (Sub)classes. Evid Based Complement Alternat Med (2016) 0.77
Importance of Apolipoprotein A-I in Multiple Sclerosis. Front Pharmacol (2015) 0.76
Partial Amelioration of Peripheral and Central Symptoms of Huntington's Disease via Modulation of Lipid Metabolism. J Huntingtons Dis (2016) 0.76
Altered Cholesterol Intracellular Trafficking and the Development of Pathological Hallmarks of Sporadic AD. J Parkinsons Dis Alzheimers Dis (2015) 0.76
Altered cholesterol biosynthesis causes precocious neurogenesis in the developing mouse forebrain. Neurobiol Dis (2016) 0.75
Food-induced changes of lipids in rat neuronal tissue visualized by ToF-SIMS imaging. Sci Rep (2016) 0.75
Comparative alteration in atherogenic indices and hypocholesteremic effect of palm oil and palm oil mill effluent in normal albino rats. Heliyon (2015) 0.75
Higher Plasma LDL-Cholesterol is Associated with Preserved Executive and Fine Motor Functions in Parkinson's Disease. Aging Dis (2016) 0.75
Low-density lipoprotein receptor-related protein 1 is a novel modulator of radial glia stem cell proliferation, survival, and differentiation. Glia (2016) 0.75
Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots. Prog Neurobiol (2015) 0.75
Scope and limitations of yeast as a model organism for studying human tissue-specific pathways. BMC Syst Biol (2015) 0.75
Cholesterol Retards Senescence in Bone Marrow Mesenchymal Stem Cells by Modulating Autophagy and ROS/p53/p21(Cip1/Waf1) Pathway. Oxid Med Cell Longev (2016) 0.75
Circulating Cholesterol Levels May Link to the Factors Influencing Parkinson's Risk. Front Neurol (2017) 0.75
Cholesterol as a modifying agent of the neurovascular unit structure and function under physiological and pathological conditions. Metab Brain Dis (2017) 0.75
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32
Regulation of the mevalonate pathway. Nature (1990) 18.25
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (2010) 18.09
Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A (1993) 15.04
Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science (1988) 13.54
The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell (1984) 12.54
ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science (2012) 10.42
The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron (2008) 10.19
Nuclear receptors and lipid physiology: opening the X-files. Science (2001) 8.76
An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature (1996) 7.86
Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA (2000) 6.55
Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron (2005) 6.20
Mutations in the human Sonic Hedgehog gene cause holoprosencephaly. Nat Genet (1996) 5.70
Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A (1993) 5.68
Midlife cardiovascular risk factors and risk of dementia in late life. Neurology (2005) 5.12
Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest (2000) 5.07
Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 5.00
Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem (1997) 4.81
ApoE promotes the proteolytic degradation of Abeta. Neuron (2008) 4.75
Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol (2003) 4.71
Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A (1998) 4.49
ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron (2004) 4.21
Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet (1997) 4.11
Drug treatment of lipid disorders. N Engl J Med (1999) 3.86
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature (2012) 3.80
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology (2010) 3.58
Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. Neurology (2001) 3.56
The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. Science (2011) 3.52
Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science (1991) 3.42
Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab (2006) 3.35
Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res (2004) 3.30
ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Neurology (1997) 3.04
Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J Biol Chem (1987) 3.04
Reelin, lipoprotein receptors and synaptic plasticity. Nat Rev Neurosci (2006) 2.95
Cholesterol metabolism in the brain. Curr Opin Lipidol (2001) 2.94
The differential miscibility of lipids as the basis for the formation of functional membrane rafts. Biochim Biophys Acta (1998) 2.94
Mechanisms and functions of Hedgehog signalling across the metazoa. Nat Rev Genet (2011) 2.93
Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta (1987) 2.90
Apolipoprotein E structure: insights into function. Trends Biochem Sci (2006) 2.86
Defective forebrain development in mice lacking gp330/megalin. Proc Natl Acad Sci U S A (1996) 2.84
Expression of apolipoprotein E during nerve degeneration and regeneration. Proc Natl Acad Sci U S A (1986) 2.80
Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry (2008) 2.72
Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med (2004) 2.72
The unfoldomics decade: an update on intrinsically disordered proteins. BMC Genomics (2008) 2.72
Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem (1994) 2.66
Lipoprotein receptors in the nervous system. Annu Rev Biochem (2001) 2.61
Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci (2011) 2.60
Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol (2004) 2.57
Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron (2007) 2.55
Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci U S A (1996) 2.48
Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol (2002) 2.41
High cholesterol level is essential for myelin membrane growth. Nat Neurosci (2005) 2.34
Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic. J Clin Invest (1983) 2.30
cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci U S A (1999) 2.20
ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem (2004) 2.19
Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology (2007) 2.17
Mutations in the very low-density lipoprotein receptor VLDLR cause cerebellar hypoplasia and quadrupedal locomotion in humans. Proc Natl Acad Sci U S A (2008) 2.15
Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice: isoform-specific effects on neurodegeneration. J Neurosci (1999) 2.15
Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes? Bioessays (2003) 2.13
Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J Biol Chem (2003) 2.11
The blood-brain barrier and immune function and dysfunction. Neurobiol Dis (2009) 2.08
High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology (2005) 2.07
Homozygous deletion of the very low density lipoprotein receptor gene causes autosomal recessive cerebellar hypoplasia with cerebral gyral simplification. Am J Hum Genet (2005) 2.06
Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J Neurosci (2006) 2.01
Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 2.01
Clusterin: a forgotten player in Alzheimer's disease. Brain Res Rev (2009) 2.00
Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med (2004) 1.99
BDNF function and intracellular signaling in neurons. Histol Histopathol (2010) 1.99
Genetic variations and treatments that affect the lifespan of the NPC1 mouse. J Lipid Res (2007) 1.99
Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology (2008) 1.97
Body cholesterol metabolism in man. I. The equilibration of serum and tissue cholesterol. J Clin Invest (1962) 1.92
Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J Lipid Res (1998) 1.92
Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proc Natl Acad Sci U S A (2005) 1.91
Oxysterols: friends, foes, or just fellow passengers? Arterioscler Thromb Vasc Biol (2002) 1.89
Mutations in LRP2, which encodes the multiligand receptor megalin, cause Donnai-Barrow and facio-oculo-acoustico-renal syndromes. Nat Genet (2007) 1.85
High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Mol Psychiatry (2012) 1.84
SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat Cell Biol (2008) 1.83
Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology (2007) 1.81
APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J Biol Chem (2003) 1.80
Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol (2002) 1.79
Control of cholesterol turnover in the mouse. J Biol Chem (2001) 1.78
Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol (2005) 1.76
The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J Biol Chem (2005) 1.74
Apolipoprotein J: structure and tissue distribution. Biochemistry (1990) 1.73
Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications. Trends Pharmacol Sci (2008) 1.71
Behavioural, physiological and morphological analysis of a line of apolipoprotein E knockout mouse. Neuroscience (1998) 1.68
Do oxysterols control cholesterol homeostasis? J Clin Invest (2002) 1.67
Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol (2004) 1.66
The Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART): an adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischemic stroke. Int J Stroke (2008) 1.65
Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration. Proc Natl Acad Sci U S A (2002) 1.65
Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J Clin Invest (1991) 1.64
Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. J Biol Chem (1995) 1.61
Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. J Lipid Res (2005) 1.60
7-Dehydrocholesterol-dependent proteolysis of HMG-CoA reductase suppresses sterol biosynthesis in a mouse model of Smith-Lemli-Opitz/RSH syndrome. J Clin Invest (2001) 1.55
Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest (1994) 1.54
Knockout of the abetalipoproteinemia gene in mice: reduced lipoprotein secretion in heterozygotes and embryonic lethality in homozygotes. Proc Natl Acad Sci U S A (1998) 1.53
Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer's disease: a systematic review and meta-analysis. Neuroepidemiology (2011) 1.48
Lipoprotein uptake by neuronal growth cones in vitro. Science (1987) 1.47
Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol (2009) 1.47
PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. J Clin Invest (2005) 1.58
Nitric oxide-donating atorvastatin attenuates neutrophil recruitment during vascular inflammation independent of changes in plasma cholesterol. Cardiovasc Drugs Ther (2013) 1.40
Safety considerations for statins. Curr Opin Lipidol (2002) 1.29
Rupture of the atherosclerotic plaque: does a good animal model exist? Arterioscler Thromb Vasc Biol (2003) 1.11
Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. Am J Pathol (2007) 0.97
Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Drugs (2013) 0.94
Pharmacological interactions of statins. Atheroscler Suppl (2002) 0.92
Synthesis, structure and conformation of partially-modified retro- and retro-inverso psi[NHCH(CF3)]Gly peptides. Chemistry (2003) 0.87
Thiol supplementation inhibits metalloproteinase activity independent of glutathione status. Biochem Biophys Res Commun (2007) 0.84
Olive oil phenols modulate the expression of metalloproteinase 9 in THP-1 cells by acting on nuclear factor-kappaB signaling. J Agric Food Chem (2010) 0.84
Everolimus inhibits monocyte/macrophage migration in vitro and their accumulation in carotid lesions of cholesterol-fed rabbits. J Pharmacol Exp Ther (2008) 0.82
Endogenous proteolytic activity in a rat model of spontaneous cerebral stroke. Brain Res (2003) 0.82
Pharmacokinetic interactions between statins and fibrates. Am J Cardiol (2005) 0.82
Drug-drug interaction with statins. Expert Rev Clin Pharmacol (2008) 0.81
Perivascular carotid collar placement induces neointima formation and outward arterial remodeling in mice independent of apolipoprotein E deficiency or Western-type diet feeding. Atherosclerosis (2007) 0.80
In vitro inhibitory effect of lercanidipine on cholesterol accumulation and matrix metalloproteinases secretion by macrophages. J Cardiovasc Pharmacol (2004) 0.79
Free cholesterol alters macrophage morphology and mobility by an ABCA1 dependent mechanism. Atherosclerosis (2010) 0.76
Dietary polyphenols and regulation of gelatinase expression and activity. Thromb Haemost (2005) 0.76
Hypolipidemic therapy for the metabolic syndrome. Pharmacol Res (2006) 0.75
[Rhabdomyolysis]. Ann Ital Med Int (2002) 0.75